PDGFRB and chronic myelogenous leukemia, BCR-ABL1 positive: Imatinib is a TKI inhibitor primarily used in human chronic myeloid leukemia but also in gastrointestinal stromal tumors due to its inhibition of c-KIT, PDGFR, and ABL kinases.